Stable gastric pentadecapeptide BPC 157-NO-system relation

Current Pharmaceutical Design

Volumn 20, Issue 7, 2014, Pages 1126-1135

  Sikiric, Predrag ^a   Seiwerth, Sven ^a   Rucman, Rudolf ^a   Turkovic, Branko ^a   Rokotov, Dinko Stancic ^a   Brcic, Luka ^a   Sever, Marko ^a   Klicek, Robert ^a   Radic, Bozo ^a   Drmic, Domagoj ^a   Ilic, Spomenko ^a   Kolenc, Danijela ^a   Aralica, Gorana ^a   Stupnisek, Mirjana ^a   Suran, Jelena ^a   Barisic, Ivan ^a   Dzidic, Senka ^a   Vrcic, Hrvoje ^a   Sebecic, Bozidar ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Arrhythmias; Chronic heart failure; Pentadecapeptide BPC 157; Pulmonary hypertension; Thrombocytopenia; Thrombosis

Indexed keywords

GLYCYLGLUTAMYLPROLYLPROLYLPROLYLGLYCYLLYSYLPROLYLALANYLASPARTYLASPARTYLALANYLGLYCYLLEUCYLVALINE; NITRIC OXIDE; PEPTIDE FRAGMENT; PROTEIN;

ANIMAL; CARDIOVASCULAR DISEASES; DISEASE MODEL; DRUG EFFECTS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; STOMACH MUCOSA; WOUND HEALING;

ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; GASTRIC MUCOSA; HUMANS; NITRIC OXIDE; PEPTIDE FRAGMENTS; PROTEINS; WOUND HEALING;

EID: 84895139801     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113190990411     Document Type: Article

References (146)

1. Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993; 87: 313-27.
2. Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach and vascular response. Inflammopharmacol 2006; 14: 214-21.
3. Sikiric P, Seiwerth S, Brcic L, et al. Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Possible significance and implications for novel mediator. Curr Pharm Des 2010; 16: 1224-34.
4. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011; 17: 1612-32.
5. Sikiric P, Seiwerth S, Rucman R, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem. 2012; 19: 126-32.
6. Sikiric P, Seiwerth S, Rucman R, et al. Toxicity by NSAIDs. Counteraction by Stable Gastric Pentadecapeptide BPC 157. Curr Pharm Des. 2013; 19: 76-83.
7. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6.
8. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
9. Moncada S, Palmer RM, Higgs EA. Biosynthesis of nitric oxide from Larginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol 1989; 38: 1709-15.
10. Taylor CT, Moncada S. Nitric oxide, cytochrome C oxidase, and the cellular response to hypoxia. Arterioscler Thromb Vasc Biol 2010; 30: 643-7.
11. Erusalimsky JD, Moncada S. Nitric oxide and mitochondrial signaling: from physiology to pathophysiology. Arterioscler Thromb Vasc Biol 2007; 27: 2524-31.
12. Moncada S. Nitric oxide: discovery and impact on clinical medicine. J R Soc Med 1999; 92: 164-9.
13. Lopez-Belmonte J, Whittle BJR, Moncada S. The actions of nitric oxide donors in the prevention or induction of injury to the rat gastric mucosa. Br J Pharmacol 1993; 108: 73-8.
14. Whittle BJR, Boughton-Smith NK, Moncada S. Biosynthesis and role of the endothelium-derived vasodilator, nitric oxide in gastric mucosa. Ann. NY Acad Sci 1992; 664: 126-39.
15. Brennan PA, Moncada S. From pollutant gas to biological messenger: the diverse actions of nitric oxide in cancer. Ann R Coll Surg Engl 2002; 84: 75-7815.
16. Sikiri P, Seiwerth S, Grabarevi Z, et al. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. Eur J Pharmacol. 1997; 332: 23-33.
17. Turkovic B, Sikiric P, Seiwerth S, et al. Stable gastric pentadecapeptide BPC 157 studied for inflammatory bowel disease (PLD116, PL14736, Pliva) induces nitric oxide synthesis. Gastroenterology 2004; 126: 287.
18. Lovric-Bencic M, Sikiric P, Hanzevacki JS, et al. Doxorubicinecongestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse. J Pharmacol Sci 2004; 95: 19-26.
19. [19] Sikiric P, Seiwerth S, Grabarevic Z, et al. The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides. Life Sci. 1994; 54: PL63-8.
20. Hrelec M, Klicek R, Brcic L, et al. Abdominal aorta anastomosis in rats and stable gastric pentadecapeptide BPC 157, prophylaxis and therapy. J Physiol Pharmacol. 2009; 60 Suppl 7: 161-5.
21. Seiwerth S, Sikiric P, Grabarevic Z, et al. BPC 157's effect on healing. J Physiol Paris 1997; 91: 173-8.
22. Mikus D, Sikiric P, Seiwerth S, et al. Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns 2001; 27: 817-27.
23. Sikiric P, Seiwerth S, Mise S, et al. Corticosteroid-impairment of healing and gastric pentadecapeptide BPC-157 creams in burned mice. Burns 2003; 29: 323-34.
24. Klicek R, Sever M, Radic B, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. J Pharmacol Sci. 2008; 108: 7-17.
25. Vuksic T, Zoricic I, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. Surg Today 2007; 37: 768-77.
26. Sever M, Klicek R, Radic B, et al. Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats. Dig Dis Sci. 2009; 54: 2070-83.
27. Cesarec V, Becejac T, Misic M, et al. Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy. Eur J Pharmacol 2012; 701: 203-212.
28. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res 2003; 21: 976-83.
29. Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. J Orthop Res 2006; 24: 1109-17.
30. Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today 2008; 38: 716-25.
31. Pevec D, Novinscak T, Brcic L, et al. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit 2010; 16: 81-88.
32. Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol 2009; 60 Suppl 7: 191-6.
33. Stupnisek M, Franjic S, Drmic D, et al. Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin or aspirin. Thromb Res 2012; 129: 652-9.
34. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol 201; 110: 774-80.
35. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res 2006; 24: 982-9.
36. Krivic A, Majerovic M, Jelic I, et al. Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone. Inflamm Res 2008; 57: 205-10.
37. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res 2010; 28: 1155-61.
38. Gjurasin M, Miklic P, Zupancic B, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regul Pept 2010; 160: 33-41.
39. Tudor M, Jandric I, Marovic A, et al. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. Regul Pept 2010; 160: 26-32.
40. Sebecic B, Nikolic V, Sikiric P, et al. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation. Bone 1999; 24: 195-202.
41. Keremi B, Lohinai Z, Komora P, et al. Antiinflammatory effect of BPC 157 on experimental periodontitis in rats. J Physiol Pharmacol 2009; 60 Suppl 7: 115-22.
42. Tkalcevic VI, Cuzic S, Brajsa K, et al. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur J Pharmacol 2007; 570: 212-21.
43. Silverman ES, Khachigian LM, Santiago FS, Williams AJ, Lindner V, Collins T. Vascular smooth muscle cells express the transcriptional corepressor NAB2 in response to injury. Am J Pathol 1999; 155: 1311-7.
44. Ilic S, Drmic D, Zarkovic K, et al. Ibuprofen hepatic encephalopathy, hepatomegaly, gastric lesion and gastric pentadecapeptide BPC 157 in rats. Eur J Pharmacol. 2011; 667: 322-9.
45. Albert J, Walle HN, Li N, Frostell C, Hjemdaht P. Neither endogenous nor inhaled nitric oxide influences the function of circulating platelets in healthy volunteers. Clinical Sci 1999; 97: 345-53.
46. Krejcy K, Schmetterer L, Kastner J, et al. Role of nitric oxide in hemostatic system activation in vivo in humans. Arterioscler Thromb Vasc Biol 1995; 15: 2063-7.
47. Grabarevic Z, Tisljar M, Artukovic B, et al. The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks. J Physiol Paris 1997; 91: 139-49.
48. Balenovic D, Bencic ML, Udovicic M, et al. Inhibition of methyldigoxin-induced arrhythmias by pentadecapeptide BPC 157: a relation with NO-system. Regul Pept 2009; 156: 83-9.
49. Balenovic D, Barisic I, Prkacin I, et al. Mortal furosemidehypokalemia-disturbances in rats NO-system related. Shorten survival by L-NAME. Therapy benefit with BPC 157 more than with L-arginine. J Clin Exp Cardiolog 2012; 3: 201.
50. Barisic M, Balenovic D, Klicek R, et al. Mortal hyperkalemia disturbance in rats is NO-system related. The life saving effect of pentadecapeptide BPC 157. Regul Pept 2013; 181C: 50-66.
51. Boban-Blagaic A, Blagaic V, Romic Z, et al. The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. The effect of N(G)-nitro-L-arginine methyl ester and L-arginine. Med Sci Monit 2006; 12: 36-45.
52. Amadeu TP, Costa AM. Nitric oxide synthesis inhibition alters rat cutaneous wound healing. J Cutan Pathol 2006; 33: 465-473.
53. Shukla A, Rasik AM, Shankar R. Nitric oxide inhibits wounds collagen synthesis. Mol Cell Biochem 1999; 200: 27-33
54. Polat C, Arikan Y, Gokce C, et al. The effect of NG-nitro Larginine methyl ester on colonic anastomosis after increased intraabdominal pressure. Langenbecks Arch Surg 2007; 392: 197-202.
55. Erbil Y, Calis A, Berber E, Mercan S. The effect of intraoperative colonic lavage with NG-nitro-L-arginine methyl ester (L-NAME) on anastomotic healing in the presence of left-sided colonic obstruction in the rat. Surg Today 2000; 30: 421-425.
56. Uzbay IT, Yesilyurt O, Celik T, et al. Effects of agmatine on ethanol withdrawal syndrome in rats. Behav Brain Res 2000; 107: 153-59.
57. Zou JY, Martinez DB, Neafsey EJ, Collins MA. Binge ethanolinduced brain damage in rats: effect of inhibitors of nitric oxide synthase. Alcohol Clin Exp Res 1996; 20: 1406-11.
58. Adams ML, Sewing BN, Chen J, et al. Nitric oxide-related agents alter alcohol withdrawal in male rats. Alcohol Clin Exp Res 1995; 19: 195-9
59. Demiryurek AT, Demiryurek S. Cardiotoxicity of digitalis glycosides: roles of autonomic pathways, autacoids and ion channels. Auton Autacoid Pharmacol 2005; 25: 35-52.
60. Pabla R, Curtis MJ. Effects of NO modulation on cardiac arrhythmias in the rat isolated heart. Circ Res 1995; 77: 984-92.
61. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-42.
62. Sikiric, P, Mazul, B, Seiwerth, S, Grabarevic, Z, Rucman, R, Petek, M, et al. Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress. Dig Dis Sci 1997; 42: 661-71.
63. Sikiric P, Gyires K, Seiwerth S, et al. The effect of pentadecapeptideBPC 157 on inflammatory, non-inflammatory, direct and indirect pain and capsaicin neurotoxicity. Inflammopharmacol 1993; 2: 121-7.
64. Kalogjera L, Ries M, Baudoin T, Ferencic Z, Trotic R, Pegan B. Dose-dependent protective effect of BPC 157 on capsaicin-induced rhinitis in rats. Eur Arch Otorhinolaryngol 1997; 254 Suppl 1: S9-11.
65. Sikiric P, Seiwerth S, Grabarevic Z, et al. The beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin and capsaicin neurotoxicity. Dig Dis Sci 1996; 41: 1604-14.
66. Veljaca, M, Chan, K, Guglietta, A. Digestion of h-EGF, h-TGF alpha and BPC-15 in human gastric juice. Gastroenterology 1995; 108: 761.
67. Veljaca M, Lesch CA, Sanchez B, Low J, Guglietta A. Protection of BPC-15 on TNBS-induced colitis in rats: Possible mechanisms of action. Gastroenterology 1995; 108: 936.
68. Fadda F, Rossetti ZL. Chronic ethanol consumption: from neuroadaptation to neurodegeneration. Prog Neurobiol 1998; 56: 385-431.
69. Blagaic AB, Blagaic V, Romic Z, Sikiric P. The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. Eur J Pharmacol 2004; 499: 285-90.
70. Prkacin I, Separovic J, Aralicia G, et al. Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD116), and propranolol, but not ranitidine. J Physiol Paris 2001; 95: 315-24.
71. Prkacin I, Aralica G, Perovic D, et al. Chronic cytoprotection: pentadecapeptide BPC 157, ranitidine and propranolol prevent, attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats. J Physiol Paris 2001; 95: 295-301.
72. Prkacin I, Staresinic M, Suknaic S, et al. Reduction of Doppler shift of otherwise increased blood flow velocity in v. cava inferior and v. portae of chronically alcohol drinking portal hypertensive rats by gastric pentadecapeptide BPC 157 (PL-10). Gastroenterology 2002; 122: 353.
73. Jelovac N, Sikiri P, Rucman R, et al. A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine. Biol Psychiatry 1998; 43: 511-9.
74. Jelovac N, Sikiric P, Rucman R, et al. Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats. Eur J Pharmacol 1999; 379: 19-31.
75. Sikiric P, Marovic A, Matoz W, et al. A behavioral study of the effect of pentadecapeptide BPC 157 in ParkinsonTs disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6tetrahydropropyridine. J. Physiol (Paris) 1999; 93: 505-12.
76. Sikiric P, Separovic J, Buljat G, et al. The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt's test and chronic unpredictable stress in rats. A comparison with antidepressants. J Physiol Paris 2000; 94: 99-104.
77. Sikiric P, Jelovac N, Jelovac-Gjeldum A, et al. Anxiolytic effect of BPC-157, a gastric pentadecapeptide: shock probe/burying test and light/dark test. Acta Pharmacol Sin. 2001; 22: 225-30.
78. Sikiric P, Jelovac N, Jelovac-Gjeldum A, et al. Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances. Acta Pharmacol Sin 2002; 23: 412-22.
79. Boban Blagaic A, Blagaic V, Mirt M, et al. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. Eur J Pharmacol 2005; 512: 173-9.
80. Egli M. Peptides: their role in excess alcohol drinking and their promise as therapeutic tool. Physiol Behav 2003; 79: 89-93.
81. Cohen C, Perrault G, Sanger DJ. Evidence for the involvement of dopamine receptors in ethanol-induced hyperactivity in mice. Neuropharmacol 1997; 36: 1099-108.
82. Malinowska B, Napiorkowska-Pawlak D, Pawlak R, et al. Ifenprodil infl uences changes in mouse behavior related to acute and chronic ethanol administration. European J Pharmacol 1999; 377: 13-9.
83. Tracy HA Jr, Wayner MJ. Losartan blocks diazepam and ethanol effects on air righting. Alcohol 1998; 16: 93-99.
84. Daniell LC. Alteration of general anesthetic potency by agonists andantagonists of the polyamine binding site of the polyamine binding site of the N-methly-D-aspartate receptor. J Pharmacol Exp Ther 1992; 261: 304-10.
85. Zink BJ, Schultz CH, Stern SA, et al. Effects of ethanol and naltrexone in a model of traumatic brain injury with hemorrhagic shock. Alcohol Clin Exp Res 2001; 25: 916-23.
86. Dar MS. Involvement of kappa-opioids in the mouse cerebellar adenosinergic modulation of ethanol-induced motor incoordination. Alcohol Clin Exp Res 1998; 22: 444-54.
87. Popova NK, Ivanova EA. 5-HT(1A) receptor antagonist p-MPPI attenuates acute ethanol effects in mice and rats. Neurosci Lett 2002; 322: 1-4.
88. Costall B, Jones BJ, Kelly ME. Ondansetron inhibits a behavioralconsequence of withdrawing from drugs of abuse. Pharmacol Biochem Behav 1990; 36: 339-44.
89. Mehta AK, Ticku MK. Ethanoland diazepam-withdrawal hyper locomotion is not due to 5-HT3 receptor stimulation. Pharmacol Biochem Behav 1993; 45: 755-7.
90. Grant KA, Hellevuo K, Tabakoff B. The 5-HT3 antagonist MDL 72222 exacerbates ethanol withdrawal seizures in mice. Alcohol Clin Exp Res 1994; 18: 410-14.
91. Smith JW, Little HJ. Differential effects of a dihydropyridine calcium channel antagonist on the components of ethanol tolerance. Brain Res 2000; 863: 9-19.
92. Wallis CJ, Rezazadeh SM, Lal H. GM1 ganglioside reduces ethanol intoxication and the development of ethanol dependence. Alcohol 1995; 12: 573-80.
93. French TA, Masserano JM, Weiner N: Infl uence of thyrotropinreleasing hormone and catecholaminergic interactions on CNS ethanol sensitivity. Alcohol Clin Exp Res 1993; 17: 99-106.
94. Adams ML, Cicero TJ. Alcohol intoxication and withdrawal: The role of nitric oxide. Alcohol 1998; 16: 153-8.
95. witkowski M, Budzy ski J, Kopocka M, et al. Parameters of the functional and morphological status of the upper digestive tract in alcoholdependent male patients with depression and alexithymia in the context of autonomic nervous system activity and nitric oxide plasma level. Med Sci Monit 2004; 10: 68-74.
96. Lavallee M, Takamura M, Parent R, Thorin E. Crosstalk between endothelin and nitric oxide in the control of vascular tone. Heart Fail Rev 2001; 6: 265-76.
97. Ozaki K, Yamamoto T, Ishibashi T, Matsubara T, Nishio M, Aizawa Y. Regulation of endothelial nitric oxide synthase and endothelin-1 expression by fluvastatin in human vascular endothelial cells. Jpn J Pharmacol 2001; 85: 147-54.
98. Wagner FD, Buz S, Knosalla C, Hetzer R, Hocher B. Modulation of circulating endothelin-1 and big endothelin by nitric oxide inhalation following left ventricular assist device implantation. Circulation 2003; 108 Suppl 1: 278-84.
99. Wittstein IS, Kass DA, Pak PH, Maughan WL, Fetics B, Hare JM. Cardiac nitric oxide production due to angiotensin-converting enzyme inhibition decreases beta-adrenergic myocardial contractility in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001; 38: 429-35.
100. Cannan CR, Burnett JC, Lerman A. Enhanced coronary vasoconstriction to endothelin B receptor activation in experimental chronic heart failure. Circulation 1996; 93: 646-51.
101. Cannan CR, Verghese M, Lerman A. New insight into coronary endothelial dysfunction. Role of endotehlin. J Lab Clin Med 1998; 131: 300-5.
102. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346: 732-6.
103. Berger R, Strecker K, Huelsmann M, et al. Prognostic power of neurohumoral parameters in chronic heart failure depends on clinical stage and observation period. J Heart Lung Transpl 2003; 22: 1037-45.
104. Pacher R, Bergler-Klein J, Globits S, et al. Plasma big endothelin-1 concentrations in congestive heart failure compared to systemic hypertension. Am J Cardiol 1993; 71: 1293-9.
105. Scheele CW, Frankenhuis MT. Stimulation of the metabolic rate in broilers and the occurrence of metabolic disorders. In: van der Honing Y, Close WH, Eds. Enerqy metabolism of farm animals. Wageningen, the Netherlands. European Association of Animal Production Publication Pudoc 1989; 43: 25l-5.
106. Wideman RF Jr, Kirby YK, Ismail M, Bottje WG, Moore RW, Vardeman RC. Supplemental L-arginine attenuates pulmonary hypertension syndrome (ascites) in broilers. Poult Sci 1995; 74: 323-30.
107. Rees DD, Palmer RM, Moncada S. Role of endotheliumderived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989; 86: 3375-8.
108. Tamir H, Ratner S. Enzymes of arginine metabolism in chicks. Arch Biochem Biophys 1963; 102: 249-58.
109. Tamir H, Ratner S. A study of ornithine, citrulline and arginine synthesis in growing chicks. Arch Biochem Biophys 1963; 102: 259-69.
110. Bosnjak ZJ, Graf BM, Sikiric P, Stowe DF. Protective effects of newly isolated gastric peptide following hypoxic and reoxygenation injury in the isolated guinea pig heart. FASEB J 1994; 8: A12.
111. Ercan ZS, Ilhan M, Kilinc M, Turker RK. Arrhythmogenic action of endothelin peptides in isolated perfused whole hearts from guinea pigs and rats. Pharmacology 1996; 53: 234-40.
112. Clausen T. Hormonal and pharmacological modification of plasma potassium homeostasis, Fundam Clin Pharmacol 2010; 24: 595-605.
113. Hack JB, Woody JH, Lewis DE, Brewer K, Meggs WJ. The effect of calcium chloride in treating hyperkalemia due to acute digoxin toxicity in a porcine model. J Toxicol Clin Toxicol 2004; 42: 337-42.
114. Ilic S, Drmic D, Franjic S, et al. Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions. Life Sci 2011; 88: 535-42.
115. Ilic S, Drmic D, Zarkovic K, et al. High hepatotoxic dose of paracetamol produces generalized convulsions and brain damage in rats. A counteraction with the stable gastric pentadecapeptide BPC 157 (PL 14736). J Physiol Pharmacol 2010; 61: 241-50.
116. Sikiric P, Seiwerth S, Grabarevic Z, et al. Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agentinduced gastrointestinal lesions and adjuvant arthritis in rats. J Physiol Paris 1997; 91: 113-22.
117. Akita M, Kuwahara M, Tsubone H, Sugano S. ECG changes during furosemide-induced hypokalemia in the rat. J Electrocardiol 1998; 31: 45-9.
118. Simons P, Nadra I, McNally PG. Metabolic alkalosis and myoclonus. Postgrad Med J 2003; 79: 414-5.
119. Sanguinetti MC, Jurkiewicz NK. Role of external Ca2+ and K+ in gating of cardiac delayed rectifier K+ currents. Pflugers Arch 1992; 420: 180-6.
120. Reungjui S, Pratipanawatr T, Johnson RJ, Nakagawa T. Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia. Curr Opin Nephrol Hypertens 2008; 17: 470-6.
121. Ilic S, Brcic I, Mester M, et al. Over-dose insulin and stable gastric pentadecapeptide BPC 157. Attenuated gastric ulcers, seizures, brain lesions, hepatomegaly, fatty liver, breakdown of liver glycogen, profound hypoglycemia and calcification in rats. J Physiol Pharmacol 2009; 60 Suppl 7: 107-14.
122. Shapiro JI, Banerjee A, Reiss OK, Elkins N. Acute and chronic hypokalemia sensitize the isolated heart to hypoxic injury. Am J Physiol 1998; 274: 598-604.
123. Driessen JJ. Neuromuscular and mitochondrial disorders: what is relevant to the anaesthesiologist? Curr Opin Anaesthesiol 2008; 2: 350-5.
124. Hastings JC, Winkle WV Jr, Barker E, Hines D, Nichols W. Effect of suture materials on healing wounds of the stomach and colon. Surg Gynecol Obstet 1975; 140: 701-7.
125. Skorjanec S, Dolovski Z, Kocman I, et al. Therapy for unhealed gastrocutaneous fistulas in rats as a model for analogous healing of persistent skin wounds and persistent gastric ulcers: stable gastric pentadecapeptide BPC 157, atropine, ranitidine, and omeprazole. Dig Dis Sci 2009; 54: 46-56.
126. Amadeu TP, Costa AM. Nitric oxide synthesis inhibition alters rat cutaneous wound healing. J Cutan Pathol 2006; 33: 465-73.
127. Shukla A, Rasik AM, Shankar R. Nitric oxide inhibits wounds collagen synthesis. Mol Cell Biochem 1999; 200: 27-33.
128. Polat C, Arikan Y, Gokce C, et al. The effect of NG-nitro Larginine methyl ester on colonic anastomosis after increased intraabdominal pressure. Langenbecks Arch Surg 2007; 392: 197-202.
129. Erbil Y, Calis A, Berber E, Mercan S. The effect of intraoperative colonic lavage with NG-nitro-L-arginine methyl ester (L-NAME) on anastomotic healing in the presence of left-sided colonic obstruction in the rat. Surg Today 2000; 30: 421-5.
130. Bilic I, Zoricic I, Anic T, et al. Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice. Life Sci 2001; 68: 1905-12.
131. Sikiric P, Separovic J, Buljat G, et al. Gastric mucosal lesions induced by complete dopamine system failure in rats. The effects of dopamine agents, ranitidine, atropine, omeprazole and pentadecapeptide BPC 157. J Physiol Paris 2000; 94: 105-10
132. Tohyama Y, Sikiri P, Diksic M. Effects of pentadecapeptide BPC 157 on regional serotonin synthesis in the rat brain: alpha-methylL-tryptophan autoradiographic measurements. Life Sci 2004; 76: 345-57.
133. Petrovic I, Dobric I, Drvis P, et al. An experimental model of prolonged esophagitis with sphincter failure in the rat and the therapeutic potential of gastric pentadecapeptide BPC 157. J Pharmacol Sci 2006; 102(3): 269-77.
134. Dobric I, Drvis P, Petrovic I, et al. Prolonged esophagitis after primary dysfunction of the pyloric sphincter in the rat and therapeutic potential of the gastric pentadecapeptide BPC 157. J Pharmacol Sci 2006; 102: 269-77.
135. Petrovic I, Dobric I, Drmic D, et al. BPC 157 therapy to detriment sphincters failure-esophagitis-pancreatitis in rat and acute pancreatitis patients low sphincters pressure. J Physiol Pharmacol 2011; 62: 527-34.
136. Jandric I, Vrcic H, Jandric Balen I, et al. Salutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incontinence models in female rats. Med Sci Monit 2013; 19: 93-102.
137. Sandor Zs, Vincze A, Jadus MR, Dohoczky Cs, Erceg D, Szabo S. The protective effect of newly isolated peptide PL-10 in the iodoacetamide colitis model in rats. Gastroenterology 1997; 112: A400.
138. Khomenko T, Szabo S, Deng XM, Sandor Z, Gombos Z, Yoshida M. Cell proliferation, transcription factor Egr-1 and growth factors in experimental ulcerative colitis after treatment with PL 14736: In vitro and in vivo studies. Gastroenterology 2003; 124: A493.
139. Pawlik WW, Sikiric P, Brzozowski T, et al. Acceleration of ulcer healing by pentadecapeptide BPC 157 in rats. Involvement of endogenous prostaglandins and gastric secretion. Gastroenterology 2004; 126: 541.
140. Mózsik G, Sikiric P, Seiwerth S. Pentadecapeptide BPC 157(PLD116, PL14736, Pliva) infl uences ATP energy system and antagonizes 0. 6 M HCland 96% ethanol-gastric lesion in rat. Digestion 2005; 73 (Suppl. 2): 41.
141. Bódis B, Karádi O, Németh P, Dohoczky C, Kolega M, Mózsik G. Evidence for direct cellular protective effect of PL-10 substances (synthesized parts of body protection compound, BPC) and their specificity to gastric mucosal cells. Life Sci 1997; 61(16): PL 243-8.
142. Bódis B, Karádi O, Nagy L, Dohoczky C, Kolega M, Mózsik G. Direct cellular effects of some mediators, hormones and growth factor-like agents on denervated (isolated) rat gastric mucosal cells. J Physiol Paris 1997; 91: 183-7.
143. Xue XC, Wu YJ, Gao MT, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004; 10: 1032-6.
144. Xue XC, Wu YJ, Gao MT, et al. Study of the protective effects of pentadecapeptide BPC 157 on skin cut wounds in small type pigs. Chin J New Drugs 2004; 13: 602-5.
145. Wood JD. The first nobel prize for integrated systems physiology: Ivan Petrovich Pavlov, 1904. Physiology (Bethesda) 2004; 19: 326-30.
146. Urist MR. The first three decades of bone morphogenetic protein. Osteologie 1996; 4: 207-33.